Bank of Montreal
NTLA icon

Bank of Montreal’s Intellia Therapeutics NTLA Stock Holding History

Bank of Montreal’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,500
Closed -$258K – 4881
2020
Q2 		$258K Buy
+10,500
New +$178K ﹤0.01% 2598

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of Montreal's NTLA Position: Q1 2025 in Review

Bank of Montreal sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 35,586 shares — an estimated $415K sold.

Bank of Montreal first reported a position in NTLA in Q3 2016 and held it in 28 quarters. The position peaked at $9.08M in Q1 2022. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Bank of Montreal reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bank of Montreal sold 35,586 Intellia Therapeutics shares in Q1 2025, an estimated $415K.
  • Bank of Montreal first reported a position in Intellia Therapeutics in Q3 2016 and held it in 28 quarters.
  • Bank of Montreal's Intellia Therapeutics position peaked at $9.08M in Q1 2022.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Bank of Montreal's 13F filing for Q1 2025, filed 13 May 2025.